Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose Technology Entitled "Low Glycemic Sugar Composition."
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose Technology Entitled "Low Glycemic Sugar Composition."
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose technology platform. The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent # 11,898,184, entitled "Low Glycemic Sugar Composition" developed within this platform.
紐約，2024年1月30日（GLOBE NEWSWIRE）——DSS Inc.（紐約證券交易所美國股票代碼：DSS）對該公司進行了大量投資的Impact Biomedical Inc.（IBIO）很高興地宣佈其創新的Laetose技術平台進入一個里程碑。美國專利商標局（USPTO）已頒發了在該平台上開發的美國專利號11,898,184，題爲 “低血糖成分”。
The Laetose technology demonstrates compelling potential in reducing caloric intake and glycemic index in foods, while also inhibiting tumor necrosis factor alpha (TNF-α), a cytokine associated with inflammatory chronic diseases.
Laetose技術在減少食物中的卡路里攝入量和血糖指數方面顯示出巨大的潛力，同時還可以抑制腫瘤壞死因子α（TNF-α），一種與炎症性慢性病相關的細胞因子。
The patented formulation is a novel combination of one or more sugars and myo-inositol, with potential to inhibit the inflammatory and metabolic response of sugar alone. This marks the first Laetose patent issued in the U.S., emphasizing IBIO's commitment to discovering, developing, and patenting unique technologies to address unmet needs in human healthcare. The term of this US patent will expire in 2037.
這種專利配方是一種或多種糖和肌醇的新型組合，有可能單獨抑制糖的炎症和代謝反應。這標誌着美國頒發的第一項Laetose專利，強調了IBIO致力於發現、開發和申請專利獨特技術，以滿足人類醫療保健領域未滿足的需求。這項美國專利的期限將在2037年到期。
The patented Laetose composition consists of an effective amount of sugar and myo-inositol, with potential applications in therapeutic administration to reduce or limit inflammatory or metabolic diseases (e.g., diabetes). The composition mitigates a TNF-α response to the sugar.
獲得專利的Laetose組合物由有效量的糖和肌醇組成，有可能應用於治療中，以減少或限制炎症或代謝性疾病（例如糖尿病）。該組合物可減輕腫瘤壞死因子α對糖的反應。
Potential Applications and Market Impact:
潛在應用和市場影響：
- US Inflammatory Disease Treatment Market: Estimated at $35B (source: Precedence Research 2022)
- US Diabetes Treatment Market: Currently at $30B and projected to grow to $61B by 2028 (source: GlobeNewswire 2022)
-
US Refined Sugar Production Market: Valued at $12B and expected to grow to $26B by 2028 (source: Knowledge Sourcing Intelligence)
- 美國炎症性疾病治療市場：估計爲350億美元（來源：Precence Research 2022）
- 美國糖尿病治療市場：目前爲300億美元，預計到2028年將增長至610億美元（來源：GlobeNewsWire 2022年）
- 美國精製糖生產市場：價值120億美元，預計到2028年將增長至260億美元（來源：知識採購情報）
Impact Biomedical CEO Frank D. Heuszel commented, "This is another demonstration of our commitment to address critical unmet needs in human healthcare. We are accelerating discussions with potential licensing and development partners to move Laetose rapidly towards the market in the US and other countries worldwide."
Impact Biomedical首席執行官弗蘭克·D.Heuszel評論說：“這再次表明了我們致力於解決人類醫療保健領域未滿足的關鍵需求。我們正在加快與潛在許可和開發合作伙伴的討論，以將Laetose迅速推向美國和全球其他國家的市場。”
About Impact Biomedical, Inc.: Impact Biomedical Inc. ("IBIO") discovers, confirms, and patents unique science and technologies resulting in new offerings in human healthcare and wellness. IBIO works closely with licensing, co-development, joint ventures, and other relationships to bring these offerings to market. For more information, visit Impact Biomedical, Inc.
關於Impact Biomedical, Inc.：Impact Biomedical Inc.（“IBIO”）發現、確認了獨特的科學和技術併爲其申請了專利，從而爲人類醫療保健和保健領域提供了新的產品。IBIO與許可、共同開發、合資企業和其他關係密切合作，將這些產品推向市場。欲了解更多信息，請訪問 Impact 生物醫學有限公司
About DSS, Inc.: DSS is a multinational company operating businesses within four diversified market sectors. For more information on DSS, visit DSS World.
關於DSS，Inc.：DSS是一家跨國公司，在四個多元化的市場領域開展業務。有關 DSS 的更多信息，請訪問 DSS 世界。
Safe Harbor Disclosure: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.
安全港披露：本新聞稿包含1933年《證券法》第27A條和1934年《證券交易法》第21E條所指的前瞻性陳述。這些陳述受風險和不確定性的影響，可能導致實際結果或事件與預測存在重大差異。提醒讀者不要過分依賴前瞻性陳述，這些陳述僅代表截至當日。
Investor Relations and Media Contact:
投資者關係和媒體聯繫人：
Contact:
聯繫人：
DSS Inc. Investor Relations
DSS Inc. 投資者關係
IR@dssworld.com
IR@dssworld.com
+1 (585) 565-2422
+1 (585) 565-2422
譯文內容由第三人軟體翻譯。